The five-year research partnership will see BCFNZ give the Ferrier Institute $500,000 to progress a significant breakthrough made by chemists at the Institute to create a life-saving breast cancer vaccine.
Ferrier Research Institute chemists are making gains in the area of cancer immunotherapy—described by leading journal Science as the ‘Breakthrough of the Year’ in 2013.
The Institute is developing a synthetic cancer vaccine technology that can activate tumour-specific T cells, producing a targeted immune response. This synthetic cancer vaccine causes rejection of cancer in several types of animal models.
Ferrier Institute director Professor Richard Furneaux says the technology is almost there. “We just need to get it to the next level of testing—human clinical trials.”
Professor Gavin Painter, who leads the chemistry team at Ferrier, says the support of BCFNZ is crucial.
“Getting a new therapy to human clinical trials requires significant investment, and an intensive campaign of chemistry, biology and regulatory compliance.
“Our success to date has been made possible because we work with the exceptional immunology research group led by Professor Ian Hermans at the Malaghan Institute of Medical Research here in Wellington, a relationship built up in a seven-year strategic collaboration.”
Evangelia Henderson, chief executive at BCFNZ says: “We went looking for a research partner who would give us the best shot of moving toward our vision of zero deaths from breast cancer. We were blown away by the calibre of the Ferrier team, the work they’d already done in the exciting field of immunotherapy and vaccines, and the strength of their international partnerships. It was a no-brainer for us.”
Cancer immunotherapy has caused a paradigm shift in cancer treatment, with a focus on targeting the body’s own immune system to fight cancer cells rather than introducing toxic agents to attack tumours directly. This line of research has led to the production of cancer vaccines which are showing promising results when used in certain situations; they are well tolerated by the body, have fewer side effects than current chemotherapy treatments and may be more effective in the long-term.
The successful immunotherapy treatment platform pioneered at Ferrier in collaboration with the Malaghan Insitute of Medical Research, has led to the establishment of biotechnology company Avalia Immunotherapies, which aims to commercialise the vaccine technology to help patients. Avalia’s chief executive officer is Victoria alumna Dr Shivali Gulab, a former NZBIO Young Bioscientist of the Year who is based in New York driving the progress of the vaccine technology towards human clinical trials.
For 20 years the Ferrier Research Institute has had an extensive working relationship with the Albert Einstein College of Medicine in New York which has resulted in successful drug trials. These include some of the most powerful enzyme inhibitors ever reported including Forodesine as a targeted therapy for a variety of haematological cancers, and Ulodesine as an orally available drug to treat severe gout.